Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience

Introduction. Hepatitis C (HCV) continues to be the leading indication for liver transplantation (LT). Sustained virological response (SVR) rates to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy for recurrent HCV in Genotype 1 (G1) LT recipients have been disappointing (30-40%). Experie...

Full description

Bibliographic Details
Main Authors: Nabiha Faisal, MD, FCPS, Eric M. Yoshida, Marc Bilodeau, Philip Wong, Mang Ma, Kelly W. Burak, Bandar Al-Judaibi, Eberhard L. Renner, Leslie B. Lilly
Format: Article
Language:English
Published: Elsevier 2014-09-01
Series:Annals of Hepatology
Subjects:
Boceprevir
Telaprevir
Sustained virological response
Early virological response
Drug-drug interaction
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119312529

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119312529

Similar Items